Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Apr 27;82(10):1671–1676. doi: 10.1054/bjoc.2000.1211

The expression profile for the tumour suppressor gene PTEN and associated polymorphic markers

J A Hamilton 1,#, L M D Stewart 1,#, L Ajayi 2, I C Gray 1,2, N E Gray 1,3, K G Roberts 1, G J Watson 1, A V Kaisary 2, D Snary 1
PMCID: PMC2374512  PMID: 10817502

Abstract

PTEN, a putative tumour suppressor gene associated with prostate and other cancers, is known to be located within the chromosomal region 10q23.3. Transcription of the PTEN gives rise to multiple mRNA species. Analyses by Northern blots, using cell lines which express PTEN together with cell lines which have lost the PTEN or carry a truncated version of the gene, has allowed us to demonstrate that the pseudogene is not transcribed. In addition, 3′ RACE studies confirmed that the multiple mRNA species arising from the gene probably result from the use of alternative polyadenylation sites. No evidence for tissue- or cell-specific patterns of transcription was found. Analysis by 5′ RACE placed the putative site for the start of transcription around 830 bp upstream of the start codon. A map of the location of the PTEN gene with a series of overlapping YAC, BAC and PACs has been constructed and the relative position of eight microsatellite markers sited. Two known and one novel marker have been positioned within the gene, the others are in flanking regions. The more accurate location of these markers should help in future studies of the extent of gene loss. Several polymorphisms were also identified, all were within introns. Four of the common polymorphisms appear to be linked. In blood, DNA from 200 individuals, including normal, BPH and prostate cancer patients, confirmed this link. Only two samples of 200 did not carry the linked haplotype, both were patients with advanced prostate cancer. It is possible that such rearrangements within PTEN could be evidence of predisposition to prostate cancer in this small number of cases. © 2000 Cancer Research Campaign

Keywords: PTEN, microsatellite markers, polymorphisms, prostate, transcription

Full Text

The Full Text of this article is available as a PDF (110.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aveyard J. S., Skilleter A., Habuchi T., Knowles M. A. Somatic mutation of PTEN in bladder carcinoma. Br J Cancer. 1999 May;80(5-6):904–908. doi: 10.1038/sj.bjc.6690439. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bose S., Wang S. I., Terry M. B., Hibshoosh H., Parsons R. Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas. Oncogene. 1998 Jul 9;17(1):123–127. doi: 10.1038/sj.onc.1201940. [DOI] [PubMed] [Google Scholar]
  3. Brownstein M. J., Carpten J. D., Smith J. R. Modulation of non-templated nucleotide addition by Taq DNA polymerase: primer modifications that facilitate genotyping. Biotechniques. 1996 Jun;20(6):1004-6, 1008-10. doi: 10.2144/96206st01. [DOI] [PubMed] [Google Scholar]
  4. Cairns P., Evron E., Okami K., Halachmi N., Esteller M., Herman J. G., Bose S., Wang S. I., Parsons R., Sidransky D. Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene. 1998 Jun 18;16(24):3215–3218. doi: 10.1038/sj.onc.1201855. [DOI] [PubMed] [Google Scholar]
  5. Cairns P., Okami K., Halachmi S., Halachmi N., Esteller M., Herman J. G., Jen J., Isaacs W. B., Bova G. S., Sidransky D. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res. 1997 Nov 15;57(22):4997–5000. [PubMed] [Google Scholar]
  6. Cheney I. W., Johnson D. E., Vaillancourt M. T., Avanzini J., Morimoto A., Demers G. W., Wills K. N., Shabram P. W., Bolen J. B., Tavtigian S. V. Suppression of tumorigenicity of glioblastoma cells by adenovirus-mediated MMAC1/PTEN gene transfer. Cancer Res. 1998 Jun 1;58(11):2331–2334. [PubMed] [Google Scholar]
  7. Chumakov I. M., Rigault P., Le Gall I., Bellanné-Chantelot C., Billault A., Guillou S., Soularue P., Guasconi G., Poullier E., Gros I. A YAC contig map of the human genome. Nature. 1995 Sep 28;377(6547 Suppl):175–297. doi: 10.1038/377175a0. [DOI] [PubMed] [Google Scholar]
  8. Coy J. F., Sedlacek Z., Bächner D., Delius H., Poustka A. A complex pattern of evolutionary conservation and alternative polyadenylation within the long 3"-untranslated region of the methyl-CpG-binding protein 2 gene (MeCP2) suggests a regulatory role in gene expression. Hum Mol Genet. 1999 Jul;8(7):1253–1262. doi: 10.1093/hmg/8.7.1253. [DOI] [PubMed] [Google Scholar]
  9. Dahia P. L., FitzGerald M. G., Zhang X., Marsh D. J., Zheng Z., Pietsch T., von Deimling A., Haluska F. G., Haber D. A., Eng C. A highly conserved processed PTEN pseudogene is located on chromosome band 9p21. Oncogene. 1998 May 7;16(18):2403–2406. doi: 10.1038/sj.onc.1201762. [DOI] [PubMed] [Google Scholar]
  10. Di Cristofano A., Pesce B., Cordon-Cardo C., Pandolfi P. P. Pten is essential for embryonic development and tumour suppression. Nat Genet. 1998 Aug;19(4):348–355. doi: 10.1038/1235. [DOI] [PubMed] [Google Scholar]
  11. Duerr E. M., Rollbrocker B., Hayashi Y., Peters N., Meyer-Puttlitz B., Louis D. N., Schramm J., Wiestler O. D., Parsons R., Eng C. PTEN mutations in gliomas and glioneuronal tumors. Oncogene. 1998 Apr 30;16(17):2259–2264. doi: 10.1038/sj.onc.1201756. [DOI] [PubMed] [Google Scholar]
  12. Feilotter H. E., Nagai M. A., Boag A. H., Eng C., Mulligan L. M. Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene. 1998 Apr 2;16(13):1743–1748. doi: 10.1038/sj.onc.1200205. [DOI] [PubMed] [Google Scholar]
  13. Fujii G. H., Morimoto A. M., Berson A. E., Bolen J. B. Transcriptional analysis of the PTEN/MMAC1 pseudogene, psiPTEN. Oncogene. 1999 Mar 4;18(9):1765–1769. doi: 10.1038/sj.onc.1202492. [DOI] [PubMed] [Google Scholar]
  14. Giri D., Ittmann M. Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma. Hum Pathol. 1999 Apr;30(4):419–424. doi: 10.1016/s0046-8177(99)90117-x. [DOI] [PubMed] [Google Scholar]
  15. Gray I. C., Phillips S. M., Lee S. J., Neoptolemos J. P., Weissenbach J., Spurr N. K. Loss of the chromosomal region 10q23-25 in prostate cancer. Cancer Res. 1995 Nov 1;55(21):4800–4803. [PubMed] [Google Scholar]
  16. Gray I. C., Stewart L. M., Phillips S. M., Hamilton J. A., Gray N. E., Watson G. J., Spurr N. K., Snary D. Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN. Br J Cancer. 1998 Nov;78(10):1296–1300. doi: 10.1038/bjc.1998.674. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kim S. K., Su L. K., Oh Y., Kemp B. L., Hong W. K., Mao L. Alterations of PTEN/MMAC1, a candidate tumor suppressor gene, and its homologue, PTH2, in small cell lung cancer cell lines. Oncogene. 1998 Jan 8;16(1):89–93. doi: 10.1038/sj.onc.1201512. [DOI] [PubMed] [Google Scholar]
  18. Knudson A. G., Jr Overview: genes that predispose to cancer. Mutat Res. 1991 Apr;247(2):185–190. doi: 10.1016/0027-5107(91)90013-e. [DOI] [PubMed] [Google Scholar]
  19. Li D. M., Sun H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res. 1997 Jun 1;57(11):2124–2129. [PubMed] [Google Scholar]
  20. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S. I., Puc J., Miliaresis C., Rodgers L., McCombie R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997 Mar 28;275(5308):1943–1947. doi: 10.1126/science.275.5308.1943. [DOI] [PubMed] [Google Scholar]
  21. Liaw D., Marsh D. J., Li J., Dahia P. L., Wang S. I., Zheng Z., Bose S., Call K. M., Tsou H. C., Peacocke M. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet. 1997 May;16(1):64–67. doi: 10.1038/ng0597-64. [DOI] [PubMed] [Google Scholar]
  22. Maehama T., Dixon J. E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 1998 May 29;273(22):13375–13378. doi: 10.1074/jbc.273.22.13375. [DOI] [PubMed] [Google Scholar]
  23. Maier D., Zhang Z., Taylor E., Hamou M. F., Gratzl O., Van Meir E. G., Scott R. J., Merlo A. Somatic deletion mapping on chromosome 10 and sequence analysis of PTEN/MMAC1 point to the 10q25-26 region as the primary target in low-grade and high-grade gliomas. Oncogene. 1998 Jun 25;16(25):3331–3335. doi: 10.1038/sj.onc.1201832. [DOI] [PubMed] [Google Scholar]
  24. Marsh D. J., Dahia P. L., Zheng Z., Liaw D., Parsons R., Gorlin R. J., Eng C. Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet. 1997 Aug;16(4):333–334. doi: 10.1038/ng0897-333. [DOI] [PubMed] [Google Scholar]
  25. Myers M. P., Stolarov J. P., Eng C., Li J., Wang S. I., Wigler M. H., Parsons R., Tonks N. K. P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9052–9057. doi: 10.1073/pnas.94.17.9052. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Rajagopalan L. E., Malter J. S. Regulation of eukaryotic messenger RNA turnover. Prog Nucleic Acid Res Mol Biol. 1997;56:257–286. doi: 10.1016/s0079-6603(08)61007-7. [DOI] [PubMed] [Google Scholar]
  27. Rasheed B. K., Stenzel T. T., McLendon R. E., Parsons R., Friedman A. H., Friedman H. S., Bigner D. D., Bigner S. H. PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res. 1997 Oct 1;57(19):4187–4190. [PubMed] [Google Scholar]
  28. Rastinejad F., Blau H. M. Genetic complementation reveals a novel regulatory role for 3' untranslated regions in growth and differentiation. Cell. 1993 Mar 26;72(6):903–917. doi: 10.1016/0092-8674(93)90579-f. [DOI] [PubMed] [Google Scholar]
  29. Risinger J. I., Hayes K., Maxwell G. L., Carney M. E., Dodge R. K., Barrett J. C., Berchuck A. PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res. 1998 Dec;4(12):3005–3010. [PubMed] [Google Scholar]
  30. Robertson G. P., Furnari F. B., Miele M. E., Glendening M. J., Welch D. R., Fountain J. W., Lugo T. G., Huang H. J., Cavenee W. K. In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma. Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9418–9423. doi: 10.1073/pnas.95.16.9418. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Rowley G., Saad S., Giannelli F., Green P. M. Ultrarapid mutation detection by multiplex, solid-phase chemical cleavage. Genomics. 1995 Dec 10;30(3):574–582. doi: 10.1006/geno.1995.1279. [DOI] [PubMed] [Google Scholar]
  32. Steck P. A., Pershouse M. A., Jasser S. A., Yung W. K., Lin H., Ligon A. H., Langford L. A., Baumgard M. L., Hattier T., Davis T. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 1997 Apr;15(4):356–362. doi: 10.1038/ng0497-356. [DOI] [PubMed] [Google Scholar]
  33. Tamura M., Gu J., Danen E. H., Takino T., Miyamoto S., Yamada K. M. PTEN interactions with focal adhesion kinase and suppression of the extracellular matrix-dependent phosphatidylinositol 3-kinase/Akt cell survival pathway. J Biol Chem. 1999 Jul 16;274(29):20693–20703. doi: 10.1074/jbc.274.29.20693. [DOI] [PubMed] [Google Scholar]
  34. Tashiro H., Blazes M. S., Wu R., Cho K. R., Bose S., Wang S. I., Li J., Parsons R., Ellenson L. H. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. 1997 Sep 15;57(18):3935–3940. [PubMed] [Google Scholar]
  35. Teng D. H., Hu R., Lin H., Davis T., Iliev D., Frye C., Swedlund B., Hansen K. L., Vinson V. L., Gumpper K. L. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res. 1997 Dec 1;57(23):5221–5225. [PubMed] [Google Scholar]
  36. Whang Y. E., Wu X., Suzuki H., Reiter R. E., Tran C., Vessella R. L., Said J. W., Isaacs W. B., Sawyers C. L. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5246–5250. doi: 10.1073/pnas.95.9.5246. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES